Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q2 EPS of ($0.34), $0.02 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.